Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Companies

Results 1 - 1 out of 1 displayed.
 
Search filter:
  • Search for: Company
Sort direction:
Sort direction:
 |   |   | 
Headquarters
Amsterdam, Netherlands
Main sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Anti-infectives
  • Antibodies
  • Immunotherapy
Indications:
  • Cardiovascular / cardiology
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the eye / ophthalmology
  • Diseases of the nervous system / neurology
  • Endocrine, nutritional and metabolic diseases / endocrinology
  • Genitourinary system / Urology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Musculoskeletal system and connective tissue / Orthopedics
  • Neoplasms / cancer / oncology
  • Respiratory / pulmonology
  • Skin and subcutaneous tissue / dermatology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Employees:
  • Worldwide: 1,148
Products:
  • In development: 26
  • On the market: 6
Description:
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. The company's products VYVGART and VYVGART HYTRULO are both prescription medicines, each used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

Already have a valid Biotechgate account? Login here »

Get access to Biotechgate

Download complete company profiles including product pipelines, financing rounds and management details.


to the top ↑